Product
Daratumumab/rHuPH20
2 clinical trials
3 indications
Indication
Multiple MyelomaIndication
Non-Hodgkin lymphomaIndication
B-cell lymphomaClinical trial
A Phase Ia/Ib Open-Label, Multicenter Study Evaluating the Safety and Pharmacokinetics of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma, and as a Single Agent and in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin LymphomaStatus: Terminated, Estimated PCD: 2023-03-28
Clinical trial
S1803, Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients With Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)Status: Recruiting, Estimated PCD: 2029-07-01